<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227005</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-07-1-0229</org_study_id>
    <nct_id>NCT01227005</nct_id>
  </id_info>
  <brief_title>Early Whole Blood in Patients Requiring Transfusion After Major Trauma</brief_title>
  <official_title>Early Whole Blood in Patients Requiring Transfusion After Major Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposal will assess if patients who require massive transfusion can be accurately
      predicted early after emergency department arrival and assess if the use of stored whole
      blood during initial resuscitation will reduce transfusion needs compared to transfusion with
      component therapy and thus improve outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The acquired coagulopathy of trauma is responsible for a large percentage of
      early deaths in civilian trauma practice and is a major cause of battlefield mortality.
      Widespread recognition has provided a rationale for fundamental changes in the initial
      management of severely injured patients through prevention of hypothermia, damage control
      surgery, massive transfusion protocols and early triage to intensive care units for optimized
      resuscitation. Despite these major advances, hemorrhage remains a leading cause of early
      death in both civilian trauma and military combat casualty care. However, it is unclear how
      early whole blood will affect coagulopathy in this cohort of patients as compared to the
      current standard of care. Objective/Hypothesis: The proposal will assess if patients who
      require massive transfusion can be accurately predicted early after emergency department
      arrival and assess if the use of stored whole blood during initial resuscitation will reduce
      transfusion needs compared to transfusion with component therapy and thus improve outcome.

      Study Design: As a first step in testing this hypothesis, we will test commonly utilized
      point of care analysis devices and determine their reliability in predicting transfusion
      requirements in severely injured trauma patients within 20 minutes after arrival in the
      emergency department. Furthermore, we will prospectively randomize severely injured patients
      who require a blood transfusion to receive either stored whole blood and pooled platelets or
      component therapy (packed red blood cells, fresh frozen plasma, and platelets, our current
      standard of care) and compare the ability of stored whole blood to reduce transfusion needs
      and improve clinical outcomes.

      Relevance: Severe uncontrollable coagulopathy in major trauma patients continues to be a
      major determinant of trauma mortalities. The proposed effort aims to provide an early,
      coagulopathy-based prediction model to identify patients at risk for massive transfusion.
      Moreover, our proposal intends to evaluate early stored whole blood transfusion in this at
      risk patient population and determine stored whole blood's ability to prevent or control
      severe coagulopathy compared to standard transfusion care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In a Prospective, Randomized Trial, Evaluate Transfusion of Stored Whole Blood and Pooled Platelets During Transfusion Therapy.</measure>
    <time_frame>first 24 hours after ED admission</time_frame>
    <description>Compare the ability of whole blood to reduce initial 24-hour transfusion requirements as compared to component therapy (red blood cells, plasma, and platelet units)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour Mortality</measure>
    <time_frame>First 24 hours after ED admission</time_frame>
    <description>Mortality rate at 24 hours after arrival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>first 30 days after ED admission</time_frame>
    <description>Evaluate 30-day mortality among those receiving whole blood compared to those receiving component therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Trauma/Injury Problem</condition>
  <arm_group>
    <arm_group_label>Whole Blood</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Whole Blood plus pooled platelets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Component Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Red blood cells, plasma, platelets</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Transfusion of blood products</intervention_name>
    <description>The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
    <arm_group_label>Whole Blood</arm_group_label>
    <arm_group_label>Component Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older.

          2. Meet Code 3 status; Code 3 is determined by the following criteria (Patients must meet
             at least one of the following physiologic and/or anatomic criteria):

               -  Physiologic criteria indicating high risk or life threatening injuries

               -  GCS &lt;10 (Glasgow Coma Scale)

               -  SBP &lt;90 (Systolic blood pressure)

               -  RR &lt;10 or &gt;29 (Respiratory rate)

               -  HR &gt;120 (Heart rate)

               -  intubated

               -  Base Deficit &gt; 6

               -  Anatomic criteria indicating high risk or life threatening injuries

               -  Any penetrating injury to torso, groin, or neck

               -  Amputation proximal to the ankle or wrist

               -  Uncontrolled external hemorrhage

               -  Two or more long bone fractures

               -  Pelvic fracture

               -  Paraplegia or quadriplegia

               -  Combination trauma with burns ≥ 20% BSA (body surface area)

          3. Demonstrate evidence of blood loss due to injury, requiring transfusion in the ED.

        Exclusion Criteria:

          1. Death thought to be imminent, suggesting a futile resuscitation effort

          2. Known or assumed religious objection to blood products

          3. Do not resuscitate order in place

          4. Women who present to the ED who are obviously pregnant.

          5. Patients who appear to the ED wearing the ―opt-out‖ bracelet provided at the community
             consultation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Cotton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Erber WN, Tan J, Grey D, Lown JA. Use of unrefrigerated fresh whole blood in massive transfusion. Med J Aust. 1996 Jul 1;165(1):11-3.</citation>
    <PMID>8676771</PMID>
  </reference>
  <reference>
    <citation>Mohr R, Martinowitz U, Lavee J, Amroch D, Ramot B, Goor DA. The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations. J Thorac Cardiovasc Surg. 1988 Oct;96(4):530-4.</citation>
    <PMID>3172799</PMID>
  </reference>
  <reference>
    <citation>Oberman HA. The indications for transfusion of freshly drawn blood. JAMA. 1967 Jan 9;199(2):93-7. Review.</citation>
    <PMID>5333702</PMID>
  </reference>
  <reference>
    <citation>Grosso SM, Keenan JO. Whole blood transfusion for exsanguinating coagulopathy in a US field surgical hospital in postwar Kosovo. J Trauma. 2000 Jul;49(1):145-8.</citation>
    <PMID>10912871</PMID>
  </reference>
  <reference>
    <citation>Ledgerwood AM, Lucas CE. A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile. J Trauma. 2003 May;54(5 Suppl):S68-74. Review.</citation>
    <PMID>12768106</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <results_first_submitted>May 19, 2014</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2015</results_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Bryan Cotton</investigator_full_name>
    <investigator_title>Associate Professor, Surgery</investigator_title>
  </responsible_party>
  <keyword>Transfusion</keyword>
  <keyword>Whole Blood</keyword>
  <keyword>Trauma</keyword>
  <keyword>Coagulopathy</keyword>
  <keyword>Component Therapy</keyword>
  <keyword>Civilian</keyword>
  <keyword>Military</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Whole Blood</title>
          <description>Whole Blood plus pooled platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
        </group>
        <group group_id="P2">
          <title>Component Therapy</title>
          <description>Red blood cells, plasma, platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Whole Blood</title>
          <description>Whole Blood plus pooled platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
        </group>
        <group group_id="B2">
          <title>Component Therapy</title>
          <description>Red blood cells, plasma, platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="29" upper_limit="56"/>
                    <measurement group_id="B2" value="38" lower_limit="32" upper_limit="56"/>
                    <measurement group_id="B3" value="39" lower_limit="30" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In a Prospective, Randomized Trial, Evaluate Transfusion of Stored Whole Blood and Pooled Platelets During Transfusion Therapy.</title>
        <description>Compare the ability of whole blood to reduce initial 24-hour transfusion requirements as compared to component therapy (red blood cells, plasma, and platelet units)</description>
        <time_frame>first 24 hours after ED admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole Blood</title>
            <description>Whole Blood plus pooled platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
          </group>
          <group group_id="O2">
            <title>Component Therapy</title>
            <description>Red blood cells, plasma, platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
          </group>
        </group_list>
        <measure>
          <title>In a Prospective, Randomized Trial, Evaluate Transfusion of Stored Whole Blood and Pooled Platelets During Transfusion Therapy.</title>
          <description>Compare the ability of whole blood to reduce initial 24-hour transfusion requirements as compared to component therapy (red blood cells, plasma, and platelet units)</description>
          <units>units of blood</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="24"/>
                    <measurement group_id="O2" value="13" lower_limit="5" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-hour Mortality</title>
        <description>Mortality rate at 24 hours after arrival</description>
        <time_frame>First 24 hours after ED admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole Blood</title>
            <description>Whole Blood plus pooled platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
          </group>
          <group group_id="O2">
            <title>Component Therapy</title>
            <description>Red blood cells, plasma, platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Mortality</title>
          <description>Mortality rate at 24 hours after arrival</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Mortality</title>
        <description>Evaluate 30-day mortality among those receiving whole blood compared to those receiving component therapy</description>
        <time_frame>first 30 days after ED admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole Blood</title>
            <description>Whole Blood plus pooled platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
          </group>
          <group group_id="O2">
            <title>Component Therapy</title>
            <description>Red blood cells, plasma, platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Mortality</title>
          <description>Evaluate 30-day mortality among those receiving whole blood compared to those receiving component therapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Whole Blood</title>
          <description>Whole Blood plus pooled platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
        </group>
        <group group_id="E2">
          <title>Component Therapy</title>
          <description>Red blood cells, plasma, platelets
Transfusion of blood products: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to blood product</sub_title>
                <description>Allergic reaction to blood product in WB arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>First, we failed to specifically exclude patients with severe TBI from our initial protocol. Finally, we did not use an objective scoring system to randomize patients and, therefore, did not always include patients who would have received an MT.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bryan A. Cotton, MD, MPH</name_or_title>
      <organization>University of Texas Health Science Center-Houston</organization>
      <phone>713-500-7354</phone>
      <email>bryan.a.cotton@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

